ReclutandoNCT05714085
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Fase 2 / Fase 3Merck Sharp & Dohme LLC
Condiciones: Heart Failure, Left Ventricular Systolic Dysfunction
Sedes en Ciudad de México: Instituto Nacional de Pediatria ( Site 1803)
Ver registro oficial ↗ReclutandoNCT06424288
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Fase 3Boehringer Ingelheim
Condiciones: Heart Failure
Sedes en Ciudad de México: Centro de Investigacion Biomedica y Farmaceutica, S.C.
Ver ficha informativaReclutandoNCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Fase 3Amgen
Condiciones: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Sedes en Ciudad de México: Soluciones Terapeuticas Medico Quirurgicas
Ver registro oficial ↗ReclutandoNCT07064473
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Fase 3Boehringer Ingelheim
Condiciones: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Sedes en Ciudad de México: Clinica Omega Diabetes · Instituto Nacional de Cardiologia Ignacio Chavez
Ver ficha informativaReclutandoNCT07157774
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Fase 3Eli Lilly and Company
Condiciones: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Sedes en Ciudad de México: RM Pharma Specialists - Unidad Especializada en Datos · Grupo Medico Camino Sc · Centro de Investigación Clinica Chapultepec
Ver registro oficial ↗ReclutandoNCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Fase 3Eli Lilly and Company
Condiciones: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Sedes en Ciudad de México: RM Pharma Specialists - Unidad Especializada en Datos · Grupo Medico Camino Sc · Centro de Investigación Clinica Chapultepec
Ver registro oficial ↗ReclutandoNCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Fase 3Eli Lilly and Company
Condiciones: Overweight, Prediabetic State, Prehypertension
Sedes en Ciudad de México: Gastrobariátrica Santa Fe
Ver registro oficial ↗ReclutandoNCT05712200
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Fase 3Anthos Therapeutics, Inc.
Condiciones: Atrial Fibrillation (AF)
Sedes en Ciudad de México: Anthos Investigative Site 1712
Ver ficha informativaReclutandoNCT07037459
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Fase 3Amgen
Condiciones: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Sedes en Ciudad de México: Soluciones Terapeuticas Medico Quirurgicas
Ver registro oficial ↗ReclutandoNCT07188805
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Fase 3Bayer
Condiciones: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Sedes en Ciudad de México: Hospital Infantil de México "Dr. Federico Gómez"
Ver registro oficial ↗